Justice Jones

Ms. Jizi

UWRT 1104

7 November 2017

Double Entry Journal

Sleeper, M, et al. Status of Therapeutic Gene Transfer to Treat Cardiovascular Disease in Dogs

and Cats. Journal of Veterinary Cardiology : the Official Journal of the European

Society of Veterinary Cardiology, vol. 13, no. 2, 2011, pp. 13140.

Source (Quote, Page Number, Paragraph Responses

Number, etc.)
Quote (Paragraph 11): We subsequently To treat for this heart problem, they put a
developed a procedure using an injection catheter into the animal while minimizing the
catheter (Myocath; Bioheart, Sunrise, Florida) damage. This process produces great results.
to perform multiple injections with a
minimally invasive approach, which has
yielded excellent results.

Quote (Paragraph 12): As described Gene therapy can be used to replace the genes
previously, gene transfer can be used to that are causing issues in the body. By
express a normal copy of a gene that is replicating the normal genes, the animal can
deficient in the animal. Gene therapy can also be treated.
be performed when the causative mutation is
unknown or in acquired diseases, with the
goal of increasing the concentration of a
therapeutic gene product in a tissue or organ.

Quote (Paragraph 14): The resultant gene This shows how gene therapy is a good
product, which mimicked the conformation of treatment. It prevents the progression of heart
the phosphorylated form of PLB, acted as a disease for a while. So, this can be a good
dominant negative mutant, suppressing measure for treatment until something else
progressive impairment of left ventricular can be used.
function and contractility for up to 30 weeks
in the muscle LIM protein (MLP) deficient
cardiomyopathic mouse and in the BIO 14.6
cardiomyopathic hamster (a model of limb-
girdle muscular dystrophy type F).